Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Simonetta M. Leto"'
Autor:
Simonetta M. Leto, Elena Grassi, Marco Avolio, Valentina Vurchio, Francesca Cottino, Martina Ferri, Eugenia R. Zanella, Sofia Borgato, Giorgio Corti, Laura di Blasio, Desiana Somale, Marianela Vara-Messler, Francesco Galimi, Francesco Sassi, Barbara Lupo, Irene Catalano, Marika Pinnelli, Marco Viviani, Luca Sperti, Alfredo Mellano, Alessandro Ferrero, Caterina C. Zingaretti, Alberto Puliafito, Luca Primo, Andrea Bertotti, Livio Trusolino
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-22 (2024)
Abstract The breadth and depth at which cancer models are interrogated contribute to the successful clinical translation of drug discovery efforts. In colorectal cancer (CRC), model availability is limited by a dearth of large-scale collections of pa
Externí odkaz:
https://doaj.org/article/dfe0bea706154ddd9a2dfd94e1c6c5a8
Autor:
Ron Bose, Andrea Bertotti, Samuel A. Jacobs, Livio Trusolino, John Monsey, Wei Shen, Adam C. Searleman, Giorgia Migliardi, Simonetta M. Leto, Francesca Cottino, Francesco Galimi, Naveen Jain, Shyam M. Kavuri
Supplementary Figure S1. Drug sensitivity of HER2 or KRAS mutations in soft agar colony formation assay. Supplementary Figure S2. NCI-H508 cell xenograft growth curves. Supplementary Figure S3. Neratinib sensitivity of KRAS WT and KRAS mutant colorec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29ab7e32913f3a865ca55a0d29b0a565
https://doi.org/10.1158/2159-8290.22529666
https://doi.org/10.1158/2159-8290.22529666
Autor:
Ron Bose, Andrea Bertotti, Samuel A. Jacobs, Livio Trusolino, John Monsey, Wei Shen, Adam C. Searleman, Giorgia Migliardi, Simonetta M. Leto, Francesca Cottino, Francesco Galimi, Naveen Jain, Shyam M. Kavuri
Gene sequencing and MSI Status of Patients and PDX's.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e8013312bee71612856b5ee0dca5e6
https://doi.org/10.1158/2159-8290.22529663
https://doi.org/10.1158/2159-8290.22529663
Autor:
Andrea Bertotti, Livio Trusolino, Elena Grassi, Caterina Marchiò, Caterina C. Zingaretti, Alessandro Ferrero, Irene Catalano, Valentina Vurchio, Francesca Cottino, Eugenia R. Zanella, Francesco Sassi, Martina Ferri, Simonetta M. Leto
Statistical analysis of results shown in Figure 2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b11e5ccb66349c157908fa7f95b37625
https://doi.org/10.1158/1078-0432.22490308
https://doi.org/10.1158/1078-0432.22490308
Autor:
Andrea Bertotti, Livio Trusolino, Elena Grassi, Caterina Marchiò, Caterina C. Zingaretti, Alessandro Ferrero, Irene Catalano, Valentina Vurchio, Francesca Cottino, Eugenia R. Zanella, Francesco Sassi, Martina Ferri, Simonetta M. Leto
Purpose:Approximately 20% of patients with RAS wild-type metastatic colorectal cancer (mCRC) experience objective responses to the anti-EGFR antibody cetuximab, but disease eradication is seldom achieved. The extent of tumor shrinkage correlates with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84a1ab7c1a1aca174ff891fed2c6911c
https://doi.org/10.1158/1078-0432.c.6533128
https://doi.org/10.1158/1078-0432.c.6533128
Autor:
Livio Trusolino, Andrea Bertotti, Mark Throsby, Eugenia R. Zanella, Giorgia Migliardi, Valter Torri, Irene Catalano, Francesco Sassi, Simonetta M. Leto
Signaling consequences of treatment with trastuzumab, lapatinib and their combination in HER2-positive colorectal and gastric cancer cells: Effects on downstream transducers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::759fd07e24bd31fde5689e0f7134617f
https://doi.org/10.1158/1078-0432.22461111.v1
https://doi.org/10.1158/1078-0432.22461111.v1
Autor:
Livio Trusolino, Andrea Bertotti, Mark Throsby, Eugenia R. Zanella, Giorgia Migliardi, Valter Torri, Irene Catalano, Francesco Sassi, Simonetta M. Leto
Quantitations of phosphoproteins in cell lines and tumorgrafts treated with HER2/EGFR small-molecule inhibitors and antibodies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d34cc18e15ea658ed925c33792a3d4
https://doi.org/10.1158/1078-0432.22461099.v1
https://doi.org/10.1158/1078-0432.22461099.v1
Autor:
Livio Trusolino, Andrea Bertotti, Mark Throsby, Eugenia R. Zanella, Giorgia Migliardi, Valter Torri, Irene Catalano, Francesco Sassi, Simonetta M. Leto
Purpose: Preclinical studies in HER2-amplified gastrointestinal cancer models have shown that cotargeting HER2 with a monoclonal antibody and a small molecule is superior to monotherapy with either inhibitor, but the underlying cooperative mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1637ae8ca4d42d015ebfc7c37842ba2d
https://doi.org/10.1158/1078-0432.c.6524697.v1
https://doi.org/10.1158/1078-0432.c.6524697.v1
Autor:
Simonetta M. Leto, Martina Ferri, Francesco Sassi, Eugenia R. Zanella, Francesca Cottino, Valentina Vurchio, Irene Catalano, Alessandro Ferrero, Caterina C. Zingaretti, Caterina Marchiò, Elena Grassi, Livio Trusolino, Andrea Bertotti
Purpose:Approximately 20% of patients with RAS wild-type metastatic colorectal cancer (mCRC) experience objective responses to the anti-EGFR antibody cetuximab, but disease eradication is seldom achieved. The extent of tumor shrinkage correlates with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::137bc0c2966617e1dedc44afd9b49f7b
https://hdl.handle.net/2318/1898412
https://hdl.handle.net/2318/1898412
Autor:
Patricia Jaaks, Elizabeth A. Coker, Daniel J. Vis, Olivia Edwards, Emma F. Carpenter, Simonetta M. Leto, Lisa Dwane, Francesco Sassi, Howard Lightfoot, Syd Barthorpe, Dieudonne van der Meer, Wanjuan Yang, Alexandra Beck, Tatiana Mironenko, Caitlin Hall, James Hall, Iman Mali, Laura Richardson, Charlotte Tolley, James Morris, Frances Thomas, Ermira Lleshi, Nanne Aben, Cyril H. Benes, Andrea Bertotti, Livio Trusolino, Lodewyk Wessels, Mathew J. Garnett
Publikováno v:
NATURE
Nature: international weekly journal of science, 603(7899)
Nature: international weekly journal of science, 603(7899)
Combinations of anti-cancer drugs can overcome resistance and provide new treatments1,2. The number of possible drug combinations vastly exceeds what could be tested clinically. Efforts to systematically identify active combinations and the tissues a